Physician profile
Aron Gedansky
NPI 1073074480
$1,019.14
in general payments reported to CMS, 2019-2025
13 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2024: $176 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $215.16 | 2024-2025 | Repatha, Repatha |
| Abbvie INC. | $194.08 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $124.87 | 2021 | |
| Ucb, INC. | $114.19 | 2025 | Nayzilam, Rystiggo |
| Pfizer INC. | $87.17 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $66.15 | 2025 | Nuplazid |
| Novo Nordisk INC | $46.28 | 2025 | Ozempic |
| Biogen, INC. | $38.11 | 2025 | Vumerity |
| Csl Behring | $34.01 | 2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $30.93 | 2024-2025 | Austedo Xr, Austedo Xr |
| Grifols USA, LLC | $28.53 | 2024 | Gamunex-C |
| Neurocrine Biosciences, INC. | $24.30 | 2024 | Ingrezza |
| Scilex Pharmaceuticals INC. | $15.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aron Gedansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.